SCHEMBL6136522

SCHEMBL6136522

CC(NC(=O)CCCc1ccccc1)C(=O)O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.70
HPGD P15428 1/20 0.63
HDAC1 Q13547 4/20 0.60
HDAC2 Q92769 3/20 0.60
HDAC3 O15379 2/20 0.60
HDAC8 Q9BY41 2/20 0.60
HDAC6 Q9UBN7 2/20 0.60
HDAC5 Q9UQL6 2/20 0.60
LMNA P02545 2/20 0.60
PKM P14618 1/20 0.60
KMT2A Q03164 2/20 0.59
MEN1 O00255 1/20 0.59
TSHR P16473 1/20 0.59
ALDH1A1 P00352 1/20 0.56
MAPK1 P28482 1/20 0.53
ADRA1A P35348 1/20 0.53
HDAC4 P56524 1/20 0.53
SLC6A3 Q01959 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC10 Q969S8 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136527 1.00 SMN1; SMN2 (0.70) SMN1; SMN2HPGDHDAC1HDAC2HDAC3
SCHEMBL14997395 1.00 SMN1; SMN2 (0.70) SMN1; SMN2HPGDHDAC1HDAC2HDAC3
SCHEMBL6136513 0.95 SMN1; SMN2 (0.64) SMN1; SMN2HPGDHDAC1HDAC2HDAC3
SCHEMBL6136515 0.95 SMN1; SMN2 (0.64) SMN1; SMN2HPGDHDAC1HDAC2HDAC3
SCHEMBL4323367 0.90 MEN1 (0.62) SMN1; SMN2HDAC1HDAC2HDAC3HDAC8
SCHEMBL4156227 0.90 MEN1 (0.62) SMN1; SMN2HDAC1HDAC2HDAC3HDAC8
SCHEMBL8241511 0.87 SMN1; SMN2 (0.74) SMN1; SMN2HPGDHDAC1HDAC2HDAC3
SCHEMBL14989384 0.86 SMN1; SMN2 (0.65) SMN1; SMN2HPGDHDAC1HDAC2HDAC3
SCHEMBL21485090 0.86 SMN1; SMN2 (0.65) SMN1; SMN2HPGDHDAC1HDAC2HDAC3
SCHEMBL14997394 0.86 SMN1; SMN2 (0.65) SMN1; SMN2HPGDHDAC1HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0951464-B1 N-(ARYL/HETEROARYLACETYL) AMINO ACID ESTERS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS ELAN PHARM INC (US) 2005-05-11 EP claimed
US-20250288559-A1 PREP BINDING LIGANDS POLKU THERAPEUTICS OY (FI) 2025-09-18 US disclosed
EP-4514781-A1 PREP BINDING LIGANDS Polku Therapeutics OY (FI) 2025-03-05 EP disclosed
WO-2023209191-A1 PREP BINDING LIGANDS UNIVERSITY OF HELSINKI (FI) 2023-11-02 WO disclosed
WO-2023209191-A1 PREP BINDING LIGANDS UNIVERSITY OF HELSINKI (FI) 2023-11-02 WO disclosed
EP-3283066-B1 4-PHENYLBUTYRIC ACID DERIVATIVES PHENOTEC AG (CH) 2022-05-11 EP disclosed
WO-2019197015-A1 COMPOSITION COMPRISING 4-PHENYLBUTYRIC ACID DERIVATIVES & OPIOIDS TRUOG PETER (CH) 2019-10-17 WO disclosed
EP-2599767-A1 Phenylbutyl-derivatives Lunamed AG (CH) 2013-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250288559-A1 PREP BINDING LIGANDS PREP, ERAP2, CTSA SMN1; SMN2 3319/4885HPGD 3255/4885HDAC1 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.